Iotalamic acid
| Clinical data | |
|---|---|
| Trade names | Conray, Glofil-125, Cysto-Conray II, others | 
| Other names | MI-216, iothalamate meglumine, Iothalamic acid (USAN US) | 
| AHFS/Drugs.com | Consumer Drug Information | 
| License data | 
 | 
| Routes of administration | Intravascular | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.017.181 | 
| Chemical and physical data | |
| Formula | C11H9I3N2O4 | 
| Molar mass | 613.916 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Iotalamic acid, sold under the brand name Conray, is an iodine-containing radiocontrast agent. It is available in form of its salts, sodium iotalamate and meglumine iotalamate. It can be given intravenously or intravesically (into the urinary bladder).
A radioactive formulation is also available as sodium iothalamate I-125 injection (brand name Glofil-125). It is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of people with kidney disease.